Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Apple
AAPL
|
+$953M |
| 2 |
NVIDIA
NVDA
|
+$784M |
| 3 |
Meta Platforms (Facebook)
META
|
+$753M |
| 4 |
Berkshire Hathaway Class A
BRK.A
|
+$316M |
| 5 |
Chipotle Mexican Grill
CMG
|
+$315M |
Top Sells
| 1 |
Amazon
AMZN
|
+$1.17B |
| 2 |
UnitedHealth
UNH
|
+$686M |
| 3 |
Tesla
TSLA
|
+$506M |
| 4 |
Abbott
ABT
|
+$388M |
| 5 |
Johnson & Johnson
JNJ
|
+$325M |
Sector Composition
| 1 | Technology | 20.29% |
| 2 | Healthcare | 16.94% |
| 3 | Consumer Discretionary | 12.83% |
| 4 | Consumer Staples | 9.16% |
| 5 | Industrials | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3351
FTC Solar
FTCI
$102M
| $156K | ﹤0.01% |
+4,860
| New | +$156K |
|
3352
Escalade
ESCA
$173M
| $155K | ﹤0.01% |
11,630
+1,600
| +16% | +$21.3K |
|
|
ENLC
3353
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $154K | ﹤0.01% |
+14,547
| New | +$154K |
|
|
ICVX
3354
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $153K | ﹤0.01% |
15,400
-22,100
| -59% | -$220K |
|
3355
Outdoor Holding Company Common Stock
POWW
$187M
| $152K | ﹤0.01% |
71,500
+11,100
| +18% | +$23.6K |
|
|
DXYN
3356
DELISTED
Dixie Group Inc
DXYN
| $152K | ﹤0.01% |
114,000
-20,180
| -15% | -$26.9K |
|
|
HARP
3357
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $152K | ﹤0.01% |
21,360
+1,718
| +9% | +$12.2K |
|
|
SEAC
3358
DELISTED
Seachange International Inc
SEAC
| $152K | ﹤0.01% |
18,592
+4,719
| +34% | +$38.6K |
|
3359
One Stop Systems
OSS
$122M
| $151K | ﹤0.01% |
52,600
-11,914
| -18% | -$34.2K |
|
3360
Arq
ARQ
$301M
| $150K | ﹤0.01% |
80,399
-77,846
| -49% | -$145K |
|
3361
Enlivex Therapeutics
ENLV
$25.5M
| $149K | ﹤0.01% |
56,689
+2,000
| +4% | +$5.26K |
|
3362
VYNE Therapeutics
VYNE
$8.04M
| $148K | ﹤0.01% |
36,076
+10,495
| +41% | +$43.1K |
|
|
PRDS
3363
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $148K | ﹤0.01% |
81,689
+51,189
| +168% | +$92.7K |
|
3364
Blue Ridge Bankshares
BRBS
$376M
| $148K | ﹤0.01% |
16,700
+4,100
| +33% | +$36.3K |
|
3365
Taysha Gene Therapies
TSHA
$884M
| $148K | ﹤0.01% |
224,400
-25,200
| -10% | -$16.6K |
|
3366
Torrid Holdings
CURV
$191M
| $147K | ﹤0.01% |
52,428
+31,428
| +150% | +$88.1K |
|
3367
Daxor
DXR
$55.4M
| $147K | ﹤0.01% |
15,321
+200
| +1% | +$1.92K |
|
3368
OceanPal Inc. Common Stock
OP
$8.3M
| $147K | ﹤0.01% |
3,574
+3,429
| +2,365% | +$141K |
|
3369
Tantech Holdings
TANH
$2.77M
| $147K | ﹤0.01% |
1,391
+53
| +4% | +$5.6K |
|
|
TRVG
3370
trivago
TRVG
$231M
| $147K | ﹤0.01% |
+22,227
| New | +$147K |
|
3371
Celularity
CELU
$62.2M
| $146K | ﹤0.01% |
27,441
+19,421
| +242% | +$103K |
|
|
AIIO
3372
Robo.ai Inc. Class B Ordinary Shares
AIIO
$472M
| $146K | ﹤0.01% |
+13,700
| New | +$146K |
|
|
TBIO
3373
DELISTED
Telesis Bio, Inc. Common Stock
TBIO
| $146K | ﹤0.01% |
5,128
-172
| -3% | -$4.9K |
|
3374
The RealReal
REAL
$1.08B
| $145K | ﹤0.01% |
+65,300
| New | +$145K |
|
3375
Solid Biosciences
SLDB
$413M
| $145K | ﹤0.01% |
27,670
-11,093
| -29% | -$58.1K |
|